Dapagliflozin Placebo
Sponsors
Astrazeneca AB, AstraZeneca AB, AstraZeneca, University at Buffalo, Daewoong Pharmaceutical Co. LTD.
Conditions
Chronic kidney disease (CKD) and hypertension.Cirrhosis of the liver is a condition in which the liver is scarred and damagedDapagliflozin (Forxiga)DexamethasoneDiabetesDiabetes MellitusDiabetes Mellitus, Type 2Endocrine System Diseases
Phase 2
A Two Part Phase IIa/b Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel Group Dose ranging Study to Assess Efficacy, Safety, and Tolerability of the Combination of Zibotentan and Dapagliflozin, and Dapagliflozin Monotherapy Versus Placebo in Participants with Cirrhosis with Features of Portal Hypertension
CompletedCTIS2023-505405-17-00
Start: 2022-10-07End: 2025-07-17Target: 111Updated: 2025-02-07
A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase IIb Study to Evaluate the Safety of Zibotentan/Dapagliflozin in Combination Compared to Zibotentan Monotherapy as well as Zibotentan/Dapagliflozin and Zibotentan Monotherapy Compared to Placebo in Participants with Cirrhosis
CompletedCTIS2023-506893-11-00
Start: 2024-04-19End: 2024-12-09Target: 36Updated: 2024-12-11
A Phase IIb, Randomised, Multicentre, Double-Blind Study to Evaluate the Effect of Baxdrostat in Combination with Dapagliflozin Compared with Baxdrostat on Albuminuria in Participants with Chronic Kidney Disease and High Blood Pressure
Not yet recruitingCTIS2025-522407-23-00
Target: 28Updated: 2026-02-16
Phase 3
A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and Exercise
CompletedNCT00528372
Start: 2007-09-30End: 2010-07-31Updated: 2015-10-20
A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and Exercise
CompletedNCT01095653
Start: 2010-06-30End: 2012-03-31Updated: 2017-02-06
A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone
CompletedNCT01095666
Start: 2010-06-30End: 2013-03-31Updated: 2017-09-11
Phase III Insulin Add-On Asia Regional Program - ST
CompletedNCT02096705
Start: 2014-03-31End: 2016-01-28Updated: 2017-08-09
Dapagliflozin As Additional Treatment To Liraglutide And Insulin In Patients With Type 1 Diabetes
CompletedNCT02518945
Start: 2015-08-31End: 2016-04-30Updated: 2024-01-24
Study to Evaluate Safety and Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Aged 10-24 Years
CompletedNCT02725593
Start: 2016-06-22End: 2020-04-06Updated: 2022-02-23
The Efficacy and Safety of DWP16001 in Combination With Metformin in T2DM Patients Inadequately Controlled on Metformin
Active, not recruitingNCT05505994
Start: 2022-09-28End: 2024-09-30Updated: 2024-04-04
Dapagliflozin Versus Dexamethasone Role in Pre-operative Management of Non- Diabetic Brain Tumor Patients
Not yet recruitingNCT06750458
Start: 2025-08-20End: 2026-12-20Target: 75Updated: 2025-04-22